Background Central nervous system (CNS) brain metastasis of advanced non-small cell
lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy …

Purpose: This retrospective study was undertaken to investigate the impact of initial gefitinib
or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of …

Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …

Background Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non …

Brain metastases are usual in non-small-cell lung cancer (NSCLC) with poor prognosis and
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …

Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …

Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …

Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI s) are
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …

Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …

Metastases to central nervous system (CNS) are very common in nonsmall cell lung cancer
(NSCLC) patients with epidermal growth factor receptor (EGFR)-positive mutation. Brain is …